Axiogenesis Overview
- Founded
- 2000

- Status
- Acquired/Merged
- Employees
- 32

- Latest Deal Type
- M&A
Axiogenesis General Information
Description
Producer of stem cell-based assays that enable drug development. The company's stem cell-based assays engage in production and use of transgenic and physiologically relevant tissues and cells derived from induced pluripotent stem cells and embryonic stem cells in drug development, enabling drug development enterprises to accelerate and improve drug candidate selection, lower costs and thus increase overall drug development efficiency.
Contact Information
- Nattermannallee 1, Building S20
- 50829 Cologne
- Germany
Axiogenesis Valuation & Funding
Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
---|---|---|---|---|---|---|
6. Merger/Acquisition | 18-Sep-2017 | Completed | Generating Revenue | |||
5. Later Stage VC | 03-May-2016 | Completed | Generating Revenue | |||
4. Later Stage VC | 05-Jun-2012 | Completed | Generating Revenue | |||
3. PIPE | 23-Mar-2011 | Completed | Generating Revenue | |||
2. IPO | 19-Dec-2007 | Completed | Generating Revenue | |||
1. Later Stage VC | Completed | Generating Revenue |
Axiogenesis Comparisons
Industry
00000000
00000000
PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.
Request a free trialAxiogenesis Competitors (28)
Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
---|---|---|---|---|---|---|
Absolute Antibody | Private Equity-Backed | Redcar and Cleveland, United Kingdom | 0 | 00.000 | 000000000000 | 00.000 |
000000000 00000000 | Corporation | Carlsbad, CA | 000000000 - | |||
000000 00000000000 | Formerly VC-backed | Indianapolis, IN | 00 | 000 | 000000&0 | 000 |
00000000 | Corporation | Alameda, CA | 00 | 000000000 - | ||
0000000 0000000000 | Formerly PE-Backed | Cambridge, MA | 000 | 00000 | 000000000 |
Axiogenesis Patents
Axiogenesis Recent Patent Activity
Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
---|---|---|---|---|---|
AU-2009254153-A1 | Novel treatment of heart diseases | Abandoned | 02-Jun-2008 | 00000000000 | |
US-20110081325-A1 | Novel treatment of heart diseases | Abandoned | 02-Jun-2008 | 00000000000 | 0 |
CA-2724678-A1 | Novel treatment of heart diseases | Abandoned | 02-Jun-2008 | 00000000000 | |
EP-2280710-A2 | Novel treatment of heart diseases | Withdrawn | 02-Jun-2008 | 00000000000 | 0 |
JP-2011521918-A | New treatment of heart disease | Pending | 02-Jun-2008 | A61K31/4745 | 0 |
Axiogenesis Executive Team (4)
Name | Title | Board Seat | Contact Info |
---|---|---|---|
Michelle Stevens | Director, Business Development | ||
Brian Murphy | Director, Marketing & Sales | ||
Heribert Bohlen Ph.D | Co-Founder & Chief Executive Officer |
Axiogenesis Signals
Growth Rate

Growth

Size Multiple


Key Data Points
Twitter Followers
5.5k

Similarweb Unique Visitors
15.0K

Majestic Referring Domains
314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.
Request a free trialAxiogenesis Former Investors (3)
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
---|---|---|---|---|---|
Donghai Securities | Holding Company | Minority | 000 0000 | 000000 0 | |
High-Tech Gründerfonds | Venture Capital | Minority | 000 0000 | 000000 0 | |
Venture Plus | Venture Capital | Minority | 000 0000 | 000000 0 |